Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Modality
Cell therapy
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04277221CT.gov ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) | — | Unknown | — | — | — |
NCT00323115CT.gov Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Dendritic Cell/Tumor Antigen, Adcta (this asset) | Safe Save Medical Cell Sciences & Technology Co.,Ltd. | P3 | B · 59 |
| Irinotecan | University of Cincinnati | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| Enzastaurin | Denovo Biopharma LLC | P3 | BB |
| Regorafenib | Istituto Oncologico Veneto IRCCS | P2/3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Autologous Dendritic Cell/Tumor Antigen, Adcta
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P1/2 | CCC · 50 |
| Hepatocellular Carcinoma | — | P2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Dendritic Cell/Tumor Antigen, Adcta in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-dendritic-celltumor-antigen-adcta-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →